Literature DB >> 31597745

Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex.

Sergio García-Fernández1,2, Yohann Bala3, Tom Armstrong4, María García-Castillo1,2, C A Burnham5, Meghan A Wallace5, Dwight Hardy6, Gilles Zambardi7, Rafael Cantón8,2.   

Abstract

Piperacillin-tazobactam (P/T) is a β-lactam-β-lactamase inhibitor combination frequently used in the hospital setting. Etest is a gradient diffusion method that represents an alternative to broth microdilution (BMD) for performing antimicrobial susceptibility testing. We conducted a multicenter evaluation of the performance of the new P/T Etest compared to that of BMD following U.S. Food and Drug Administration (FDA) and International Standards Organization (ISO) standard ISO 20776-2 criteria using Clinical and Laboratory Standards Institute (CLSI)-FDA and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints, respectively. A total of 977 isolates (775 Enterobacterales isolates, 119 Pseudomonas aeruginosa isolates, and 83 Acinetobacter baumannii complex isolates) were tested. Overall essential agreement (EA) was 96.4% and 96.6% for Enterobacterales when FDA and ISO 20776-2 criteria, respectively, were followed. EA was 98.3% for P. aeruginosa and 91.6% for the A. baumannii complex when both the FDA and ISO criteria were followed. Applying CLSI-FDA breakpoints, categorical agreement (CA) reached 93.0%, 93.3%, and 89.2% for the Enterobacterales, P. aeruginosa, and the A. baumannii complex, respectively. Two very major errors (VMEs; 1.1%) were found among the Enterobacterales (for 2 Klebsiella pneumoniae isolates). No additional major errors (MEs) or VMEs were found. Applying EUCAST breakpoints, CA was 94.8% and 95.8% for Enterobacterales and P. aeruginosa, respectively (no breakpoints are currently available for the A. baumannii complex). No VMEs were observed among the Enterobacterales, but 2 (0.4%) MEs were found. Among the P. aeruginosa isolates, 2 (6.9%) VMEs and 3 (3.3%) MEs were observed. These errors resulted when P/T Etest MICs were 1 doubling dilution apart from the BMD MICs. In conclusion, the new P/T Etest represents an accurate tool for performing antimicrobial susceptibility testing of Enterobacterales, P. aeruginosa, and A. baumannii complex isolates with limited category errors.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumannii complex; Enterobacteraleszzm321990; Etest; Pseudomonas aeruginosazzm321990; antimicrobial susceptibility testing; gradient diffusion; piperacillin-tazobactam

Mesh:

Substances:

Year:  2020        PMID: 31597745      PMCID: PMC6989064          DOI: 10.1128/JCM.01042-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Evaluation of the E test, a novel method of quantifying antimicrobial activity.

Authors:  D F Brown; L Brown
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

2.  Performance of the Etest for Susceptibility Testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa toward Ceftazidime-Avibactam.

Authors:  Michael Kresken; Barbara Körber-Irrgang
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

3.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

4.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Authors:  Jesús Rodríguez-Baño; María Dolores Navarro; Pilar Retamar; Encarnación Picón; Álvaro Pascual
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

Review 5.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

Review 6.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 7.  Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.

Authors:  L L Schoonover; D J Occhipinti; K A Rodvold; L H Danziger
Journal:  Ann Pharmacother       Date:  1995-05       Impact factor: 3.154

8.  Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Authors:  Patrick N A Harris; Paul A Tambyah; David C Lye; Yin Mo; Tau H Lee; Mesut Yilmaz; Thamer H Alenazi; Yaseen Arabi; Marco Falcone; Matteo Bassetti; Elda Righi; Benjamin A Rogers; Souha Kanj; Hasan Bhally; Jon Iredell; Marc Mendelson; Tom H Boyles; David Looke; Spiros Miyakis; Genevieve Walls; Mohammed Al Khamis; Ahmed Zikri; Amy Crowe; Paul Ingram; Nick Daneman; Paul Griffin; Eugene Athan; Penelope Lorenc; Peter Baker; Leah Roberts; Scott A Beatson; Anton Y Peleg; Tiffany Harris-Brown; David L Paterson
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272

Review 9.  Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.

Authors:  B Gutiérrez-Gutiérrez; J Rodríguez-Baño
Journal:  Clin Microbiol Infect       Date:  2019-04-12       Impact factor: 8.067

Review 10.  Interplay between β-lactamases and new β-lactamase inhibitors.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Nat Rev Microbiol       Date:  2019-05       Impact factor: 60.633

View more
  4 in total

1.  Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).

Authors:  Andrew Henderson; Romney Humphries
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

2.  Disk Correlates for Revised Clinical and Laboratory Standards Institute Enterobacterales Piperacillin-Tazobactam MIC Breakpoints.

Authors:  Romney Humphries; Pranita D Tamma; Amy J Mathers
Journal:  J Clin Microbiol       Date:  2022-04-21       Impact factor: 11.677

3.  Evaluation of digital dispense-assisted broth microdilution antimicrobial susceptibility testing for Pseudomonas aeruginosa isolates.

Authors:  Shawn T Clark; Patrick J Stapleton; Pauline W Wang; Yvonne C W Yau; Valerie J Waters; David M Hwang; David S Guttman
Journal:  Sci Rep       Date:  2021-04-28       Impact factor: 4.379

4.  Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types.

Authors:  Thomas Edwards; Eva Heinz; Jon van Aartsen; Alex Howard; Paul Roberts; Caroline Corless; Alice J Fraser; Christopher T Williams; Issra Bulgasim; Luis E Cuevas; Christopher M Parry; Adam P Roberts; Emily R Adams; Jenifer Mason; Alasdair T M Hubbard
Journal:  Microb Genom       Date:  2022-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.